# About Safe Wolverine: An Editorial Digest of the BPC-157 TB-500 Record

> About Safe Wolverine: an independent editorial digest summarizing the peer-reviewed research and FDA record on the BPC-157 TB-500 blend. Not a clinic, not a vendor.

An independent editorial project that reads the two-peptide blend corner against corner — every finding cited, every gap left visible.

## What Safe Wolverine is

Safe Wolverine is an independent editorial project that publishes summaries of the peer-reviewed research literature on the BPC-157 TB-500 blend. We read the two peptides the way the science presents them — as a matchup of two distinct constituents with two distinct mechanisms — and we cite every quantitative claim to a published study or an FDA record.

We are not a clinic. We do not employ clinicians, and we do not provide medical advice. We do not manufacture, sell, or distribute any product, and nothing on this site is an offer to supply any substance. Our work is editorial commentary on publicly available science.

## Why the matchup framing

The "Wolverine" blend is literally two fighters in two corners: BPC-157, a cytoprotective and pro-angiogenic peptide working through VEGFR2-Akt-eNOS [2], versus TB-500, an actin-sequestering fragment of Thymosin Beta-4 working on cell migration [3]. Racking them head-to-head is the most honest way to show what is actually established for each — and to make the empty row impossible to skim past. There is no controlled blend-level study on record [8], the "synergy" is a theoretical extrapolation, both constituents are unapproved and WADA-prohibited, and both are in FDA's 503A Category 2 [11].

That last point is why the access record gets its own page rather than a footnote. The status is also under active FDA review, with a July 2026 advisory-committee discussion scheduled [13] — which we report as a scheduled discussion, never as a settled outcome.

## The 'safe' in the name

The "safe" modifier in our name is editorial framing — a commitment to read this blend cautiously and completely, status first — not a claim that the blend is safe. Safety in humans is unestablished for both constituents [8], and the literature flags a theoretical tumor-angiogenesis concern for Thymosin Beta-4 [4]. "Safe Wolverine" describes how we cover the subject: we put the gaps and the regulatory record in plain sight rather than burying them. It is a position relative to the literature, not a statement about the substance, and not a description of any service. You can read [about this research digest](/about) here, or start with the [frequently asked questions about the blend](/faq).

---

A versus-screen reading of the BPC-157 TB-500 blend — each peptide racked against its own studies, the combination row left at NO MATCH ON RECORD, and the FDA and WADA status called before the bell, with no clinic in the corner and nothing here for sale.